The Safety and Dose-range Study of Metacavir Enteric-coated Capsules in Patients With Chronic Hepatitis B

NCT02965859 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2016-11-22

No results posted yet for this study

Summary

The study objective is to evaluate the safety and effectiveness of different doses of Metacavir Enteric-coated Capsules in treatment of chronic hepatitis B,as well as to find an appropriate clinical dosage by comparing the effect of different doses of treatment,in order to provide references of clinical trial of the next phase.

Conditions

Interventions

DRUG

Metacavir Enteric-coated Capsules 80mg

Metacavir Enteric-coated Capsules 80mg

DRUG

Metacavir Enteric-coated Capsules 160mg

Metacavir Enteric-coated Capsules 160mg

DRUG

Metacavir Enteric-coated Capsules 320mg

Metacavir Enteric-coated Capsules 320mg

DRUG

Metacavir Enteric-coated Capsules Placebo 240mg

Metacavir Enteric-coated Capsules Placebo 240mg

DRUG

Metacavir Enteric-coated Capsules Placebo 160mg

Metacavir Enteric-coated Capsules Placebo 160mg

DRUG

Metacavir Enteric-coated Capsules Placebo 320mg

Metacavir Enteric-coated Capsules Placebo 320mg

DRUG

Adefovir Dipivoxil Capsule10mg

Adefovir Dipivoxil Capsule10mg

DRUG

Adefovir Dipivoxil Capsule Placebo 10mg

Adefovir Dipivoxil Capsule Placebo 10mg

Sponsors & Collaborators

  • Guangzhou Yipinhong Pharmaceutical CO.,LTD

    lead INDUSTRY

Principal Investigators

  • Maorong Wang · 81 Military Hospital of China

  • Yonggang Li · Beijing 302 Hospital

  • Yongfeng Yang · The Second Hospital of Nanjing Medical University

  • Yanlin Yu · Wannan Medical College Yijishan Hospital

  • Jun Li · The First Affiliated Hospital with Nanjing Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-12-31
Primary Completion
2018-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02965859 on ClinicalTrials.gov